Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.
about
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejectionMHC class I signaling: new functional perspectives for an old moleculeStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationMonocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Antibody Subclass Repertoire and Graft Outcome Following Solid Organ TransplantationImmunoregulatory Effects of Everolimus on In Vitro Alloimmune ResponsesComplement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts.Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures.Delayed reendothelialization with rapamycin is rescued by the addition of nicorandil in balloon-injured rat carotid arteriesAntibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft InjuryChronic allograft rejection: a fresh look.Everolimus and sirolimus in transplantation-related but different.Innate immune mechanisms in transplant allograft vasculopathy.mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection.Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection.HLA Class I and Class II-Induced Intracellular Signaling and Molecular Associations in Primary Human Endothelial Cells.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus
P2860
Q26862195-00131A0E-E1F4-48A7-9BCA-D0AFD040A45EQ27000194-2A226E8E-1FD1-444F-A5B1-6AA466D59E9EQ27005375-ED283FFF-188F-4786-9C35-9664E672251BQ27314948-A2F21406-3B72-4AD2-B582-D99BD37F5BA7Q28076193-7AD9DCAE-EBFE-4215-BFFA-B6A0D3DDBF3CQ28550145-5733269D-A4D3-414F-A5CA-B880C866F454Q33829159-BBB5C2F4-4D3A-430B-8E8C-19DA8400B72AQ35469913-E2CF9331-ECB9-4C03-8495-FF338859DC8FQ37597272-133D8345-8D21-4CE7-ACBC-FEE52CC12F46Q37689044-DD5E8E60-D46A-418B-8A82-76AA6CC066E1Q37720377-8FB03587-0930-4045-85BD-582C3E575158Q38309271-D0190CE5-8D52-462F-9308-E330F6860C53Q38442560-4F0CF29F-2B50-4619-879B-8EA99FC55E94Q38808100-5FDDA566-E0D0-4EFA-97C2-331323D18742Q38818479-12CA727E-CCAD-42EE-89AB-1D6AE7BBE8C1Q38914374-9D0075F6-BC4C-465C-9177-76A41947FBE8Q39366396-23926044-9219-41F2-89E0-6EB4EBF7545CQ42597754-3E9EBDE9-EAAF-4016-BC3F-7BD2CD58E68CQ46258296-735374E5-5D06-4BBC-B6B9-7D2E3B837067Q47673511-2E5F1BEE-2787-4330-AEEC-2EB86DD89460Q56035477-6C268415-6269-42B6-A448-44A652A85790
P2860
Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Everolimus inhibits anti-HLA I ...... more potently than sirolimus.
@en
type
label
Everolimus inhibits anti-HLA I ...... more potently than sirolimus.
@en
prefLabel
Everolimus inhibits anti-HLA I ...... more potently than sirolimus.
@en
P2093
P2860
P356
P1476
Everolimus inhibits anti-HLA I ...... n more potently than sirolimus
@en
P2093
E Rozengurt
N M Valenzuela
P2860
P304
P356
10.1111/AJT.12669
P407
P577
2014-03-01T00:00:00Z